[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100184024":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":24,"locations":33,"responsibleParty":44,"collaborators":24,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":24,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":24,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":69,"whyStopped":24,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(R)(T)","ACTIVE_COMPARATOR","Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg",[13],"Drug: Fimasartan",{"label":15,"type":10,"description":16,"interventionNames":17},"(T)(R)","Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg",[13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Fimasartan","Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg",[9],null,{"type":20,"name":21,"description":26,"armGroupLabels":27,"otherNames":24},"Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg",[15],[29],{"name":30,"affiliation":31,"role":32},"Jae-Gook Shin, M.D, Ph.d","Division of Clinical Pharmacology","PRINCIPAL_INVESTIGATOR",[34],{"facility":35,"status":24,"city":36,"state":24,"zip":24,"country":37,"countryCode":24,"cosmosGeoPoint":38,"geoPoint":43,"contacts":24},"Inje University Busan Paik Hospital","Busan","South Korea",{"type":39,"coordinates":40},"Point",[41,42],129.03004,35.10168,{"lat":42,"lon":41},{"type":45,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100184024","phase-1-clinical-trials-for-single-oral-dose-of-60mg-fimasartan-and-single-iv-infusion-of-30mg-fimasartan-to-evaluate-the-absolute-bioavailability-of-kanarb-tablet-fimasartan-in-healthy-subjects-100184024",false,"NCT01671020","Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects","Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects","Inclusion Criteria:\n\n* age: 20 - 55 years\n* body weight: standard weight(Broca's index, Possible range is plus or minus 20percent)\n* written informed consent\n\nExclusion Criteria:\n\n* known allergy to Fimasartan\n* existing cardiac or hematological diseases\n* existing hepatic and renal diseases\n* existing gastrointestinal diseases\n* acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder\n* abnormal diet which could affect drug absorption or metabolism\n* positive drug or alcohol screening\n* smokers of 10 or more cigarettes per day\n* participation in a clinical trial during the last 90 days prior to the start of the study",true,"ALL","20 Years","55 Years",{"count":58,"type":59},16,"ACTUAL","INTERVENTIONAL",[62],"PHASE1","Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects",[65],"Healthy",[67,68],"fimasartan","absolute bioavailability","COMPLETED","2016-06-29",{"date":72,"type":73},"2016-07-01","ESTIMATED",{"date":75,"type":24},"2012-06",{"date":77,"type":59},"2012-07",{"name":5,"class":6},1]